Biogen’s Hemophilia Spin: Prelude to a Takeover?
May 03, 2016 at 10:49 AM EDT
Today’s announcement that Biogen ( BIIB ) plans to spin off its hemophilia business into a stand-alone company has more than a few analysts and investors scratching their heads. Among the many questions: Is this a prelude to a takeover?
